Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

Lower urinary tract symptoms (LUTS) in men are voiding, storage, and postmicturition symptoms that commonly arise from benign prostatic hyperplasia (BPH) — a nonmalignant, androgen-dependent proliferation of prostatic epithelial and stromal tissue that begins in the periurethral transition zone and can progress to bladder outlet obstruction. Two mechanisms coexist and most pharmacotherapy targets one or the other: a static component (the physical bulk of an enlarged gland narrowing the urethral lumen) and a dynamic component (alpha1-adrenergic-receptor-mediated smooth-muscle tone in the bladder neck, prostate, and urethra). LUTS is common, but LUTS is not synonymous with BPH — prostate cancer, urinary tract infection, neurogenic bladder, urethral stricture, and overactive bladder unrelated to prostatic enlargement can all produce an identical symptom picture, so ruling out other causes is part of every initial workup, not an afterthought. The goals of therapy are to improve or resolve bothersome symptoms, delay or prevent clinical progression, and prevent the long-term sequelae of unrelieved bladder outlet obstruction — recurrent urinary tract infection, bladder stones, and obstructive uropathy with renal impairment.^[1] Current Canadian practice follows the 2022 Canadian Urological Association (CUA) guideline update, cross-checked against the 2023 American Urological Association (AUA) guideline amendment and the 2026 European Association of Urology (EAU) guideline on non-neurogenic male LUTS.^[2][3]

LUTS are conventionally grouped into 3 domains; most patients have a mixture, but identifying which domain predominates directly shapes drug selection.

Onset is typically gradual over years and severity fluctuates over time. A sudden, severe change — especially complete inability to void — is not typical of gradually progressive BPH and should prompt evaluation for acute urinary retention or an alternative cause rather than being assumed to be a BPH flare.

• Increasing age — the single strongest risk factor; BPH is uncommon before age 40 and becomes progressively more common with each subsequent decade.
• Family history of BPH, particularly in a first-degree relative.
• Intact testicular androgen production — BPH does not develop in men castrated before puberty, underscoring the androgen dependence of the condition.
• Obesity and features of metabolic syndrome.
• Possibly type 2 diabetes and reduced physical activity, though the evidence for these is less consistent than for the factors above.

Differentiating BPH-related LUTS from its mimics

History (mandatory)

• Characterize voiding symptoms (weak/interrupted stream, dribbling, hesitancy, straining) and storage symptoms (nocturia, frequency, urgency) separately.
• Onset, progression, and degree of bother — a formal symptom inventory such as the International Prostate Symptom Score (IPSS; see below) is recommended at initial consultation, during watchful waiting, and to track treatment response.
• Details of urethral infection, instrumentation, or injury (trauma, surgery, radiation).
• Prior episodes of urinary tract infection, hematuria, or urinary retention.
• Full medication review, including over-the-counter drugs and phytotherapeutic products — diuretics, decongestants, antihistamines, and antidepressants with anticholinergic activity can all worsen LUTS.

Physical examination (mandatory)

• Abdomen — bladder distention, flank tenderness.
• External genitalia — phimosis, meatal stenosis, urethral mass or induration.
• Digital rectal examination — document prostate size, consistency, symmetry, and tenderness, and note anal tone and any rectal abnormality.

Laboratory testing

• Urinalysis (mandatory), with urine culture if bacteriuria or pyuria is found — needed to rule in/out causes other than BPH.
• PSA (recommended, selectively) — offer to patients with at least a 10-year life expectancy for whom knowledge of prostate cancer would change management, and to those for whom a PSA result would help estimate prostate volume relevant to LUTS management.^[1] This is a different clinical question from population-based prostate cancer screening in an asymptomatic man, where routine PSA screening is not generally recommended — the guidance above applies specifically to the diagnostic workup of a man who already has LUTS.

Optional, when diagnostic uncertainty exists

• Serum creatinine, urine cytology, uroflowmetry, and post-void residual (PVR).
• A frequency-volume voiding diary, especially when nocturnal polyuria is suspected as the driver of bothersome nocturia.
• Obstructive sleep apnea screening (e.g., STOP-BANG questionnaire) in men over 50 with nocturia, since untreated OSA is a treatable contributor.
• A sexual function questionnaire, particularly when a PDE5 inhibitor is being considered.

Not routinely indicated

Cytology, cystoscopy, urodynamics, radiologic imaging of the upper urinary tract, prostate ultrasound, and prostate biopsy are not part of the routine initial evaluation of typical BPH-related LUTS. Reserve these for hematuria, genuine diagnostic uncertainty, an abnormal DRE, poor response to medical therapy, or surgical planning (where cystoscopy and prostate ultrasound to determine volume and median-lobe presence become appropriate).^[1]

International Prostate Symptom Score (IPSS)

The IPSS is a validated, patient-completed, 7-question symptom inventory. Each question is scored 0 to 5 by the patient, and the 7 scores are summed to a total of 0 to 35.^[4]

Total score interpretation: 0-7 = mildly symptomatic; 8-19 = moderately symptomatic; 20-35 = severely symptomatic.^[4] An additional, separately scored quality-of-life/bother question (0 = delighted to 6 = terrible) accompanies the 7-item index in the full instrument; it is not part of the 0-35 sum but is clinically important, since treatment decisions should follow the degree of bother at least as much as the numeric score. The IPSS is a symptom-severity index, not a diagnostic test — it does not distinguish BPH from other causes of LUTS and does not correlate closely with objective measures such as prostate volume or peak flow rate, so use it to grade severity and track response to treatment, not to confirm the diagnosis.

• Improve or resolve bothersome voiding, storage, and postmicturition symptoms.
• Delay or prevent clinical progression of BPH — worsening symptoms, acute urinary retention, or the eventual need for BPH-related surgery.
• Prevent the long-term sequelae of unrelieved bladder outlet obstruction: recurrent urinary tract infection, bladder stones, and obstructive uropathy with renal impairment.
• Preserve sexual function where possible, and weigh the patient's own tolerance for sexual side effects against symptom control when selecting a drug.
• Align the treatment plan with the patient's own therapeutic goal through shared decision-making, and document that goal.^[1]

Lifestyle and behavioural measures

• Manage men with mild, non-bothersome symptoms with reassurance and active surveillance — periodic reassessment — rather than starting a drug.
• Restrict fluid intake in the hours before bedtime, particularly for men whose main complaint is nocturia.
• Reduce or avoid caffeinated beverages, alcohol, and spicy foods.
• Review medications that can worsen LUTS and adjust or avoid them where possible: diuretics, decongestants and other alpha-adrenergic agonists, antihistamines, and antidepressants with anticholinergic activity.
• Try timed or organized voiding (bladder retraining) for bothersome storage symptoms.
• Identify and treat constipation, which can worsen bladder outlet symptoms.
• Encourage weight loss and management of metabolic syndrome where present.
• Refer for pelvic floor physical therapy when a non-relaxing pelvic floor is suspected as a contributor to LUTS, pelvic/genital pain, or bowel/sexual dysfunction.
• Advise men with pedal edema to elevate their legs before bedtime to reduce nocturnal fluid redistribution and resulting nocturia.
• Use a shared decision-making aid to walk through treatment options and document the patient's own therapeutic goal.^[1]

Procedures

Surgical intervention is appropriate for men with an absolute indication — recurrent or refractory urinary retention, recurrent urinary tract infection, bladder stones, recurrent gross hematuria from prostatic hypervascularity, or renal insufficiency secondary to bladder outlet obstruction — or for men with symptom deterioration despite medical therapy, or a preference to stop medical therapy for a more definitive treatment. Modality selection depends on prostate volume, presence of a median lobe, fitness for anesthesia, anticoagulant/antiplatelet therapy, and how much the patient values preserving ejaculatory function; local urologist consultation determines what is actually available.^[1] The field continues to shift toward tissue- and ejaculation-preserving techniques as evidence for newer technologies matures.^[2][3]

BPH-related LUTS is a condition of the aging prostate and does not occur in pediatric patients — no pediatric dosing applies to any drug in this chapter.

Pregnancy and breastfeeding

BPH-related LUTS does not itself arise in pregnancy or lactation, since it occurs only in patients with a prostate. However, both finasteride and dutasteride carry a real teratogenic risk to a male fetus through partner exposure — a pregnant partner, or a partner who may become pregnant, should not handle crushed or broken 5-alpha-reductase inhibitor tablets, and condom use is advised during intercourse for men taking these drugs whose partner is or may become pregnant, since the drug is present in semen. Intact tablets can be handled normally by anyone.

Renal impairment

Silodosin requires dose reduction (4 mg once daily) at a creatinine clearance of 30-50 mL/min and should be avoided below 30 mL/min. Desmopressin requires extra caution and closer sodium monitoring in renal impairment (see Monitoring and Follow-up). New or worsening renal impairment in a man with LUTS may itself signal advanced obstructive uropathy and warrants more urgent workup and consideration of urology referral rather than routine BPH management.

Hepatic impairment

Avoid alfuzosin and silodosin in significant hepatic impairment. Tadalafil is not recommended in severe hepatic impairment. Use 5-alpha-reductase inhibitors with caution in significant liver disease.

Older adults

Nonuroselective alpha-blockers (doxazosin, terazosin) carry a meaningfully higher orthostatic hypotension and fall risk in older men — favour a uroselective agent, or dose at bedtime, where an alpha-blocker is indicated. Antimuscarinics carry cumulative anticholinergic burden that can worsen cognition and falls risk in frail older men — favour mirabegron, fesoterodine, or tolterodine over oxybutynin when an agent with lower central nervous system penetration is preferred. Desmopressin's hyponatremia risk rises substantially with age — monitor more closely in men 65 and older.

Cardiovascular disease and heart failure

An observational Canadian study found an association between alpha-blocker and/or 5-alpha-reductase inhibitor exposure and new heart failure in men over 66 years of age, with the strongest signal for nonselective alpha-blockers used alone.^[5] Weigh the benefit of symptom relief against this signal in men with existing heart failure or significant cardiovascular disease, favour a uroselective alpha-blocker where an alpha-blocker is still indicated, and monitor for new or worsening heart failure symptoms after starting therapy in this population.

Intraoperative floppy iris syndrome and cataract surgery

Alpha1-blockers — tamsulosin most consistently — are associated with intraoperative floppy iris syndrome (IFIS), a combination of iris billowing, progressive intraoperative miosis, and iris prolapse toward the surgical incision during cataract surgery.^[6] Ask every patient about current or prior alpha-blocker use before any planned cataract surgery, including men who stopped the drug months to years earlier, since the association can persist after discontinuation. This should be disclosed to the operating ophthalmologist in advance so the surgical team can plan for it, rather than discovering it intraoperatively — IFIS is manageable with advance notice and is not, on its own, a reason to withhold or stop alpha-blocker therapy for LUTS. See the Cataract Surgery Postoperative Care chapter for more detail on perioperative management.

PSA interpretation on 5-alpha-reductase inhibitor therapy

Both finasteride and dutasteride suppress serum PSA, and this must be accounted for when interpreting PSA results in a man on 5-ARI therapy. Establish a new PSA baseline at 6 months after starting a 5-alpha-reductase inhibitor and continue periodic monitoring from that new baseline. For a man who started a 5-ARI without a repeat post-treatment baseline, doubling the on-treatment PSA value provides a reasonable approximation of the untreated value when interpreting results for prostate cancer risk. Any confirmed rise in PSA from the on-treatment value while a patient remains on a 5-alpha-reductase inhibitor should prompt assessment for high-grade prostate cancer, since 5-ARI use does not eliminate prostate cancer risk.^[1]

Prostate cancer risk-reduction counselling

Neither finasteride nor dutasteride is approved in Canada for prostate cancer prevention, but randomized trial evidence shows both agents reduce the overall risk of being diagnosed with prostate cancer while on therapy — finasteride in the Prostate Cancer Prevention Trial and dutasteride in the REDUCE trial.^[7][8] This is a genuine, useful counselling point for a patient with BPH who is also concerned about his prostate cancer risk and is deciding whether to start a 5-alpha-reductase inhibitor — the risk-reduction effect is a real secondary benefit of a drug already being considered for symptom control, not a reason to start a 5-ARI in a man who has no BPH indication for one.

Depression, self-harm, suicidality, and muscle-related effects

5-alpha-reductase inhibitor therapy has been associated with an increased risk of self-harm and depression, most pronounced in the first 18 months after starting treatment, though without an increased risk of completed suicide, in a large cohort of men 66 years of age and older.^[9] Separately, Health Canada's most recent safety review (completed January 2023) found a possible link between finasteride and suicidal ideation and self-injury; screen for depression, suicidal ideation, self-harm, and related risk factors before starting a 5-alpha-reductase inhibitor and periodically during treatment, and counsel patients that these effects have been reported to persist in some cases after stopping the drug.^[10] Health Canada has also concluded that a risk of serious muscle-related adverse effects (myopathy, rhabdomyolysis) with finasteride cannot be ruled out — advise patients to promptly report unexplained muscle pain, weakness, or dark urine.^[11]

• Watchful waiting: periodic reassessment of symptoms/bother (IPSS) and screening for new red flags at intervals guided by clinical judgment.
• Alpha-blocker: reassess response and tolerability within a few weeks, since maximal response is seen within weeks; check blood pressure and orthostatic symptoms, especially with nonselective agents.
• 5-alpha-reductase inhibitor: reassess symptom response at 6 months, since full effect can take up to 6-12 months; re-baseline PSA at 6 months (see Special Populations); screen for depression/self-harm and sexual dysfunction at follow-up.
• Combination therapy: after 6-9 months of successful combination therapy, offer the option of discontinuing the alpha-blocker component; restart it if symptoms recur.^[1]
• Antimuscarinic/beta-3 agonist: assess specifically for urinary retention during the first month of treatment, when the risk is highest; reassess PVR if there is any concern; monitor for typical anticholinergic effects, and monitor blood pressure with mirabegron.
• Desmopressin: check serum sodium at baseline before starting, then again at 4-8 days and at 30 days after initiation (and after any dose increase); monitor more frequently in men 65 and older or those taking other medications associated with hyponatremia; stop if serum sodium falls below the normal range.^[1]
• Post-surgical: follow up 4-6 weeks after catheter removal with symptom reassessment (IPSS) and, if indicated, uroflowmetry/PVR; screen for adverse effects of the procedure.
• General: continue effective drug therapy indefinitely, since symptoms recur when medication is stopped; reassess for red flags — new hematuria, a rising or unexpected PSA, a DRE change, recurrent UTI, or deteriorating renal function — at every visit regardless of how well symptoms are controlled.

1. Confirm adherence and that an adequate trial duration has elapsed before calling a drug a failure — weeks for an alpha-blocker, up to 6-12 months for a 5-alpha-reductase inhibitor.
2. Re-examine for an alternative or coexisting cause of LUTS (urinary tract infection, prostatitis, prostate cancer, neurogenic bladder, urethral stricture, bladder stone) with targeted testing rather than simply escalating BPH therapy.
3. For voiding symptoms not controlled on alpha-blocker monotherapy in a man with an enlarged prostate and/or elevated PSA: add a 5-alpha-reductase inhibitor (combination therapy).
4. For persistent storage symptoms despite an alpha-blocker, with PVR not significantly elevated: add an antimuscarinic or a beta-3 agonist.
5. For persistent voiding symptoms with coexisting erectile dysfunction: add or switch to tadalafil, stabilizing on the alpha-blocker first if combining.
6. For persistent bothersome nocturia confirmed as nocturnal polyuria on a voiding diary: add desmopressin with sodium monitoring.
7. For symptoms that remain refractory despite optimized combination medical therapy, or if an absolute surgical indication develops (recurrent/refractory acute urinary retention, recurrent urinary tract infection, bladder stones, recurrent gross hematuria, renal impairment from BPH): refer for urologic/surgical evaluation.
8. Any new red flag at any point: refer or escalate immediately rather than continuing to adjust BPH medical therapy.

• Starting presumptive BPH treatment without a DRE and appropriate red-flag screening.
• Abandoning a 5-alpha-reductase inhibitor as "not working" before 6 months — its effect on symptoms and prostate volume develops slowly.
• Adding a PDE5 inhibitor to an alpha-blocker without first stabilizing the patient on the alpha-blocker — additive hypotension risk.
• Prescribing tadalafil to a patient taking any nitrate or a guanylate cyclase stimulator.
• Misinterpreting a PSA result in a man on a 5-alpha-reductase inhibitor without accounting for the drug's suppressive effect — this risks missing prostate cancer.
• Starting an antimuscarinic or beta-3 agonist in a man with a significantly elevated post-void residual or a history of spontaneous acute urinary retention without caution.
• Not asking about alpha-blocker use before a planned cataract surgery, or failing to ensure it is disclosed to the ophthalmologist.
• Recommending decongestants or other alpha-adrenergic agonists to a man with BPH-related LUTS — these can worsen bladder outlet obstruction and blunt the benefit of alpha-blocker therapy.
• Treating acute urinary retention as something to try medication for, instead of the emergency it is — immediate catheterization comes first.
• Recommending saw palmetto or other phytotherapeutic agents as an evidence-based alternative to standard pharmacotherapy — current guidance does not recommend these agents, since trial evidence has not shown a benefit over placebo.^[1]
• Forgetting to screen for depression, self-harm, and suicidal ideation before and during 5-alpha-reductase inhibitor therapy.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. BPH does not occur in pediatric patients, so no pediatric dosing applies to any drug below. Select any drug name to open its complete Pharmasist Drug Database page.

Alpha1-adrenergic receptor antagonists (alpha-blockers)

Reduce the dynamic component of bladder outlet obstruction by relaxing smooth muscle in the bladder neck, prostate, and urethra. Uroselectivity (targeting alpha1A/alpha1D receptors in the urinary tract over alpha1B receptors in vascular smooth muscle) determines the balance between ejaculatory and blood-pressure-related adverse effects; all agents have equal clinical effectiveness for symptom relief. Maximal response is typically seen within weeks.

5-alpha-reductase inhibitors

Block conversion of testosterone to dihydrotestosterone, reducing prostate volume over months and addressing the static component of obstruction. Best evidence for benefit is in men with a prostate volume over 30 cc and/or PSA over 1.5 ng/mL. Suppress serum PSA — see Special Populations for interpretation.

Phosphodiesterase type 5 inhibitor

Relaxes smooth muscle in and around the prostate; the only PDE5 inhibitor approved for daily LUTS management.

Antimuscarinics and beta-3 agonist

For bothersome storage symptoms, alone or added to an alpha-blocker, in men with mixed or storage-predominant LUTS. Use with caution, or avoid, when PVR exceeds 200-300 mL or there is a history of spontaneous acute urinary retention — the retention risk is highest in the first month of treatment.

Antidiuretic hormone analogue

For bothersome nocturia specifically due to nocturnal polyuria, confirmed on a voiding diary, that has not responded to conservative measures or other BPH therapy.

Phytotherapeutic agents (not recommended)

Serenoa repens (saw palmetto), Pygeum africanum (African plum bark), and Urtica dioica (stinging nettle) are the most commonly used plant-based preparations for LUTS. Formulation and pharmacokinetics of the active ingredients are inconsistent across products, and current guidance does not recommend phytotherapeutic agents as standard treatment for LUTS/BPH, since trial evidence has not shown a benefit over placebo.^[1]

Evidence note: drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against the current CUA guideline and the 2023 AUA guideline amendment.^[1][2]